As Per the Report, the Size of the Europe Digital Breast Tomosynthesis (DBT) Equipment Market size is valued at USD 331.89 million in 2022 and is expected to grow at a CAGR of 13.5% to reach USD 625.13 million by 2027 during the forecast period 2022 to 2027.
The increasing incidence of breast cancer, the growing awareness of the use of tomosynthesis, and the advancement in technology to develop new, innovative imaging products are the primary drivers of the European digital breast tom synthesis equipment market. Each year, approximately 2.18 million women are affected by breast cancer, and more than 627,500 women are expected to die from breast cancer. Therefore, the increase in the use of tomosynthesis over the traditional method is driving the market's growth.
According to the World Health Organization (WHO), breast cancer is the most common type of cancer in women; around 2.18 million women have breast cancer each year, with the highest number of cancer-related deaths among women. By the end of 2020, 7.85 million living women had been diagnosed with breast cancer in the past five years. In 2019, breast cancer accounted for almost 15.3% of cancer deaths among women worldwide. There are around 56,000 new breast cancer cases in the UK every year - more than 150 every day.
In Germany, 68,990 women were diagnosed with breast cancer, and 18,575 women died from the disease in 2016. In Germany, the number of breast cancer cases is estimated to increase owing to various factors such as lifestyle changes, use of contraceptives, genetic predisposition, and hormonal changes. In addition, increased awareness is leading to the use of these systems with high detection rates, driving the market.
Increasing interpretation time by radiologists is expected to hamper the market growth. Reading a DBT image set takes almost twice the time required to interpret 2D mammograms due to the majority of images produced. Additional factors such as the high cost of equipment and maintenance costs, lack of skilled professionals are limiting the growth of the European digital breast tomosynthesis (DBT) Equipment market. Moreover, the lack of reimbursement policies is another factor challenging the European digital breast tomosynthesis DBT equipment market.
This research report on the Europe Digital Breast Tomosynthesis (DBT) Equipment Market has been segmented and sub-segmented into the following categories
By End User:
Geographically, the Germany digital breast tomosynthesis dbt equipment market held a dominant position in the European digital breast tomosynthesis (DBT) equipment market in 2020, with a share of 25% in value, followed by the United Kingdom. The German market is expected to register a CAGR of 9% during the forecast period and is estimated to be valued at the US $ 1.01 billion by the end of 2027. Factors such as technological advancements in the breast imaging field, the presence of well-established healthcare infrastructure, and increasing healthcare spending will drive this regional market.
In terms of value, the United Kingdom digital breast tomosynthesis dbt equipment market is projected to grow at a CAGR of 8.5% during the forecast period, attributed to the high incidence f breast cancer and favorable reimbursement policies.
Other European regions like Spain, France, and the Netherlands will see significant growth opportunities due to improving healthcare facilities, continuous research and development, and the availability of a large patient population in the region. For example, breast cancer in France tops women's incidence and mortality rates, with 54,162 new cases and 14,000 deaths in 2017.
KEY MARKET PLAYERS
Prominent Companies dominating the Europe Digital Breast Tomosynthesis (Dbt) Equipment Market Profiled in the Report are Hologic Inc., Siemens Healthineers, Fujifilm Corporation. Other players in the market include GE Healthcare, Internazionale Medico Scientifica S.r.l. and Planmed Oy.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org